ARIAD reports net gain of $13.9 million for third quarter 2011 ARIAD Pharmaceuticals, Inc generiske lægemidler . today reported economic results for the third quarter of 2011 and supplied an revise on its corporate advancements. Berger, M.D., chairman and ceo. ‘Simultaneously, AP26113, our exclusive, investigational dual-inhibitor of ALK and EGFR, has advanced into the clinic, and we believe that it may address a major unmet medical need in two clinically essential, molecularly described subgroups of patients with non-small cell lung cancer.’ PACE Trial Completely Enrolled and Interim Data to end up being Presented at ASH ARIAD’s global Speed trial has been conducted in patients with chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia who are resistant or intolerant to either nilotinib or dasatinib, two currently available CML therapies, or anyone who has the T315I mutation of BCR-ABL that no current remedies are known to be effective.
ARIAD can be working closely with Merck in preparing its co-advertising of ridaforolimus in the U.S. Co-promotion provides ARIAD with a primary involvement in the potential industrial success of ridaforolimus and, at the same time, lays the groundwork for the infrastructure that will be employed by ARIAD for the potential potential commercialization of ponatinib upon acceptance. Interim Data from the Speed Trial Anticipated at End of Year Patient enrollment ‘s almost comprehensive in the pivotal Phase 2 PACE trial of ponatinib, ARIAD’s investigational pan-BCR-ABL inhibitor, with five of six individual cohorts now shut to enrollment and the sixth expected to close this quarter.